These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 639829)

  • 21. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
    Kirchhof PF; Fabritz CL; Franz MR
    Circulation; 1998 Jun; 97(25):2567-74. PubMed ID: 9657478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
    Breithardt G; Borggrefe M; Wiebringhaus E; Seipel L
    Am J Cardiol; 1984 Nov; 54(9):29D-39D. PubMed ID: 6496367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Observations on the anti-arrhythmic effects of propafenone].
    Ku FS
    Zhonghua Nei Ke Za Zhi; 1982 Nov; 21(11):658-61. PubMed ID: 7166067
    [No Abstract]   [Full Text] [Related]  

  • 24. [Electrophysiologic effects of propafenone in subjects with pre-existing excito-conduction disorders].
    Rizzo A; Fiorilli R; Lisanti P
    G Ital Cardiol; 1984 May; 14(5):377-8. PubMed ID: 6468820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrophysiological effects of propafenone in untreated and propafenone-pretreated guinea-pig atrial and ventricular muscle fibres.
    Delgado C; Tamargo J; Tejerina T
    Br J Pharmacol; 1985 Dec; 86(4):765-75. PubMed ID: 4075015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The treatment of arrhythmias in infants and children using propafenone].
    Dressler F; Grävinghoff L; Grütte E; Jüngst BK; Liersch R; Nomayo H; Puls I; Rautenburg HW; Schmaltz A; Schumacher G
    Monatsschr Kinderheilkd; 1985 Mar; 133(3):154-7. PubMed ID: 4010670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ECG changes and plasma concentrations of propafenone and its metabolites in a case of severe poisoning.
    Fonck K; Haenebalcke C; Hemeryck A; Belpaire F; Jordaens L; Calle P; Buylaert W
    J Toxicol Clin Toxicol; 1998; 36(3):247-51. PubMed ID: 9656983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Influence of propafenon on hemodynamics of the left ventricle and atrioventricular conduction with special reference to the WPW syndrome].
    Probst P; Pachinger O
    Z Kardiol; 1976 Mar; 65(3):213-24. PubMed ID: 1258514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term treatment with the new antiarrhythmic drug propafenone in correlation to plasma levels (author's transl)].
    Wiebringhaus E; Seipel L; Breithardt G; Loogen F
    Z Kardiol; 1977 Nov; 66(11):625-32. PubMed ID: 22958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rate-dependent effects of ajmaline and propafenone on atrioventricular conduction.
    Stark G; Schwarzl I; Stark U; Decrinis M; Tritthart HA
    Eur J Pharmacol; 1996 Aug; 310(1):29-35. PubMed ID: 8880064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-performance liquid chromatographic analysis of propafenone in human plasma samples.
    Harapat SR; Kates RE
    J Chromatogr; 1982 Jul; 230(2):448-53. PubMed ID: 7107791
    [No Abstract]   [Full Text] [Related]  

  • 32. Electrophysiological effects of a new antiarrhythmic agent, nicainoprol, in humans.
    Sen S; Rettig G; Ozbek C; Fröhlig G; Schieffer H; Bette L
    J Cardiovasc Pharmacol; 1986; 8(1):144-50. PubMed ID: 2419677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of oral propafenon on accessory pathways of atrioventricular conduction].
    Lacroix H; Frank R; Tonet JL; Fontaine G; Wajman A; Squeir S; Grosgogeat Y
    Arch Mal Coeur Vaiss; 1985 Apr; 78(4):622-7. PubMed ID: 2860884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
    von Philipsborn G; Gries J; Hofmann HP; Kreiskott H; Kretzschmar R; Müller CD; Raschack M; Teschendorf HJ
    Arzneimittelforschung; 1984; 34(11):1489-97. PubMed ID: 6543124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrophysiological effects of propafenone on isolated guinea-pig ventricular muscle and sheep Purkinje fibres.
    Tamargo J; Delgado C
    Eur J Pharmacol; 1985 Dec; 118(3):331-40. PubMed ID: 4085559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Electrophysiologic and hemodynamic effects of the new anti-arrhythmia agent diprafenone].
    Gülker H; Heuer H; Thale J; Behrenbeck T
    Z Kardiol; 1987 Jul; 76(7):411-4. PubMed ID: 3673162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity.
    Hodges M; Salerno D; Granrud G
    Am J Cardiol; 1984 Nov; 54(9):45D-50D. PubMed ID: 6388303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans.
    Ranger S; Talajic M; Lemery R; Roy D; Villemaire C; Nattel S
    Circulation; 1991 Jun; 83(6):1987-94. PubMed ID: 2040051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic and electrophysiologic effects of oral propafenone.
    Prystowsky EN; Heger JJ; Chilson DA; Miles WM; Hubbard J; Zipes DP
    Am J Cardiol; 1984 Nov; 54(9):26D-28D. PubMed ID: 6496366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers].
    Cardaioli P; Compostella L; De Domenico R; Papalia D; Zeppellini R; Libardoni M; Pulido E; Cucchini F
    G Ital Cardiol; 1986 Mar; 16(3):237-40. PubMed ID: 3732716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.